Antimicrobial peptide spampcin56-86 from scylla paramamosain and applications thereof

ABSTRACT

A Spampcin 56-86  is provided. A molecular formula of Spampcin 56-86  is C 154 H 256 N 54 O 33 S 3 , and an amino acid sequence of Spampcin 56-86  is shown in SEQ ID NO: 01.

RELATED APPLICATIONS

This application is a continuation-in-part of International patent application PCT/CN2022/100406, filed on Jun. 22, 2022, which claims priority to Chinese patent application 202110716770.6, filed on Jun. 25, 2021. International patent application PCT/CN2022/100406 and Chinese patent application 202110716770.6 are incorporated herein by reference.

REFERENCE TO AN ELECTRONIC SEQUENCE LISTING

The contents of the electronic sequence listing (SequenceListing.xml; Size: 1,944 bytes; and Date of Creation: Aug. 22, 2023) is herein incorporated by reference.

FIELD OF THE DISCLOSURE

The present disclosure relates to the field of marine molecular biotechnology, and in particular relates to an antimicrobial peptide Spampcin₅₆₋₈₆ from Scylla paramamosain and applications thereof.

BACKGROUND OF THE DISCLOSURE

It is reported that China is currently the largest producer and consumer of antibiotics in the world and is also one of the countries with the most serious drug resistant bacteria. The large amount of unregulated and irrational use of antibiotics has caused a series of problems, such as increased bacterial resistance, suppressed animal immunity, affected human health, and even damaged ecological environment. Therefore, the development of new and efficient anti-bacterial drugs and the search for effective antibiotic alternatives have become an urgent problem to be solved.

Antimicrobial peptides (AMPs) are a kind of small-molecule anti-microbial peptides and are widely distributed in animals and plants. AMPs are the first line of defense against infections of various pathogenic microorganisms and are an important part of the innate immune system. A main disease resistance mechanism of AMPs is to act on cell membranes of pathogenic microorganisms to enable the pathogenic microorganisms to have difficulty in producing resistance, so that a generation of drug resistance problems is avoided. AMPs have a broad spectrum of anti-bacterial activity, anti-fungal activity, anti-viral activity, anti-parasitic activity, and other activities. In addition, AMPs have multiple roles, such as acting as immunomodulators, signaling molecules, and anti-tumor molecules, etc. Therefore, AMPs are very attractive alternatives to traditional antibiotics and important candidates for the development of new antimicrobial drugs, and AMPs also have considerable prospects in transformation applications.

The structure of AMPs mainly consists of α-helix, β-sheet, and extended cyclic structures. Based on a number of charges carried, AMPs are classified into cationic and anionic peptides. Until now, the antimicrobial peptides database (CAMPR3) has collected 10247 natural and synthetic peptides. AMPs with a broad antimicrobial spectrum have also been found in marine animals, such as Crustins, ALFs, Penaeidins in shrimp hemolymph, Sphistin from histone H2A, glycine-rich new antimicrobial peptide (AMP) Spgly-AMP, and scygonadin and SCY2 derived from Scylla serrata with reproductive immune functions. The marine animals are living in extreme marine environments and lack acquired immunity. When pathogen infection occurs, AMPs and immune effective factors in the innate immunity fight against the pathogens. In recent years, with the continuous deterioration of the marine ecological environment, the problem of frequent occurrence of mariculture diseases has become increasingly prominent. Therefore, it is still of great significance to accelerate the research and development of novel AMPs.

BRIEF SUMMARY OF THE DISCLOSURE

A first object of the present disclosure is to provide a novel, safe, and efficient antimicrobial peptide (AMP) Spampcin₅₆₋₈₆ from Scylla paramamosain (i.e., Spampcin₅₆₋₈₆) and applications thereof.

A second object of the present disclosure is to provide applications for using the Spampcin₅₆₋₈₆.

A first technical solution is as follows.

The molecular formula of the Spampcin₅₆₋₈₆ is C₁₅₄H₂₅₆N₅₄O₃₃S₃, and the amino acid sequence of the Spampcin₅₆₋₈₆ is shown in SEQ ID NO: 01.

A second technical solution is as follows.

A method for preparing the Spampcin₅₆₋₈₆ comprises synthesizing the Spampcin₅₆₋₈₆ by a chemical solid-phase method.

A third technical solution is as follows.

An application for using the Spampcin₅₆₋₈₆ comprises preparing an anti-bacterial agent using the Spampcin₅₆₋₈₆.

In a preferred embodiment, the anti-bacterial agent has inhibitory or bactericidal effects against Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecium, Enterococcus faecalis, Listeria monocytogenes, Escherichia coli, Pseudomona aeruginosa, Aeromonas hydrophila, Aeromonas sobria, Edwardsiella tarda, Pseudomonas fluorescens, Acinetobacter baumannii, drug-resistant Staphylococcus aureus, drug-resistant Acinetobacter baumannii, and drug-resistant Escherichia coli.

A fourth technical solution is as follows.

An application for using the Spampcin₅₆₋₈₆ comprising preparing an antifungal agent using the Spampcin₅₆₋₈₆.

In a preferred embodiment, the anti-fungal agent has inhibitory and bactericidal effects against Fusarium oxysporum, Fusarium graminearum, or Fusarium solani.

A fifth technical solution is as follows.

An application for using the Spampcin₅₆₋₈₆ comprises preparing an aquatic feed additive using the Spampcin₅₆₋₈₆.

In a preferred embodiment, an active component of the aquatic feed additive comprises the Spampcin₅₆₋₈₆.

The present disclosure has the following advantages:

The Spampcin₅₆₋₈₆ of the present disclosure consists of 31 amino acids with a molecular formula of C₁₅₄H₂₅₆N₅₄O₃₃S₃, and a molecular weight of 3488.25 Daltons. The Spampcin₅₆₋₈₆ contains 7 positively charged amino acid residues, and the isoelectric point of the Spampcin₅₆₋₈₆ is 11.71. The average hydrophilicity coefficient of the Spampcin₅₆₋₈₆ is −0.410, and the Spampcin₅₆₋₈₆ is a positively charged cationic peptide.

The Spampcin₅₋₈₆ of the present disclosure has a significant anti-bacterial effect on Gram-positive bacteria, Gram-negative bacteria, and fungi. Further, the Spampcin₅₆₋₈₆ has no obvious cytotoxic effect on hemocytes of Scylla paramamosain and human embryonic kidney 293T cells (HEK 293T cells).

The Spampcin₅₆₋₈₆ of the present disclosure has wide antimicrobial spectrum, strong antibacterial activity, strong antifungal activity, and a rapid bactericidal rate.

The Spampcin₅₆₋₈₆ can be developed as anti-bacterial drugs and anti-fungal drugs and can also be applied to aquatic feed additives, which has a broad application prospect.

BRIEF DESCRIPTION OF THE DRAWING

FIGS. 1A, 1B, 1C, and 1D respectively show bactericidal kinetics of the antimicrobial peptide Spampcin₅₆₋₈₆ of Scylla paramamosain (i.e., Spampcin₅₆₋₈₆) against Staphylococcus aureus (i.e., S. aureus), Pseudomonas aeruginosa (i.e., P. aeruginosa), Aeromonas hydrophila (i.e., A. hydrophila), and Escherichia coli (i.e., E. coli) in Embodiment 3 of the present disclosure. The X-axes are time (minutes), and the Y-axes are bactericidal rates (%);

FIGS. 2A and 2B respectively show the thermal stability of Spampcin₅₆₋₈₆ against S. aureus and P. aeruginosa in Embodiment 4 of the present disclosure. The X-axes are time (hours), and the Y-axes are the OD₆₀₀ values;

FIGS. 3A, 3B, and 3C show the inhibition of Spampcin₅₆₋₈₆ against Fusarium graminearum (i.e., F. graminearum) spore germination in Embodiment 5 of the present disclosure. The concentrations of Spampcin₅₆₋₈₆ are 0 μMol (μM), 6 μM, and 12 μM, respectively;

FIGS. 4A, 4B, and 4C show the inhibition of Spampcin₅₆₋₈₆ against Fusarium oxysporum (i.e., F. oxysporum) spore germination in Embodiment 5 of the present disclosure. The concentrations of Spampcin₅₆₋₈₆ are 0 μM, 6 μM, and 12 μM, respectively;

FIG. 5A shows morphological changes of S. aureus without treatment, and FIG. shows morphological changes of S. aureus after treatment with 12 μM Spampcin₅₆₋₈₆ in Embodiment 6 of the present disclosure under scanning electron microscope (SEM) observation.

FIG. 6A shows morphological changes of P. aeruginosa without treatment, and FIG. 6B illustrates morphological changes of P. aeruginosa after treatment with 12 μM of Spampcin₅₆₋₈₆ under SEM observation in Embodiment 6 of the present disclosure.

FIGS. 7A and 7B illustrate graphs of a cytotoxicity test of Spampcin₅₆₋₈₆ using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium-phenazine methosulfate (MTS-PMS) assay. The X-axes are concentrations (μM) of Spampcin₅₆₋₈₆, and the Y-axes are cell proliferation rates (%).

DETAILED DESCRIPTION OF THE EMBODIMENTS

The technical solution of the present disclosure will be further described below in combination with the accompanying embodiments and drawings.

Embodiment 1: Preparation of an Antimicrobial Peptide Spampcin₅₆₋₈₆ from Scylla paramamosain (i.e., Spampcin₅₆₋₈₆)

An amino acid sequence of Spampcin₅₆₋₈₆ is as follows:

Arg-Arg-Ala-Ala-His-Gly-Leu-Leu-Pro-Arg-Leu-Arg-Ala-Pro-Pro-Pro-Phe-His-Lys-Arg-Cys-Val-Cys-Leu-Cys-Arg-Thr-Ala-Pro-Pro-Pro (SEQ ID NO: 01)

The Spampcin₅₆₋₈₆ was entrusted to Kingsley (Jiangsu) Co., Ltd. for chemical solid-phase synthesis, and the Spampcin₅₆₋₈₆ was obtained with a purity of more than 95%. Physicochemical parameters of the Spampcin₅₆₋₈₆ are shown in Table 1.

TABLE 1 Physicochemical parameters of the Spampcin₅₆₋₈₆ Physicochemical parameters Spampcin₅₆₋₈₆ Amino acid residue 31 Molecular weight 3488.25 Molecular formula C₁₅₄H₂₅₆N₅₄O₃₃S₃ Isoelectric point 11.71 Net charge +7 Hydrophobicity 41% Total average hydrophilicity −0.410 Molar extinction coefficient 125

The Spampcin₅₆₋₈₆ is a positively charged cationic peptide with a small molecular weight and good stability, as shown in Table 1.

Embodiment 2: Determination of Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) of the Spampcin₅₆₋₈₆

Bacterial strains involved in Embodiment 2 are as follows: Staphylococcus aureus (i.e., S. aureus), Staphylococcus epidermidis (i.e., S. epidermidis), Enterococcus Faecium (i.e., E. Faecium), Enterococcus Faecalis (i.e., E. Faecalis), Listeria Monocytogenes (i.e., L. Monocytogenes), Escherichia coli (i.e., E. coli), Pseudomona aeruginosa (i.e., P. aeruginosa), Aeromonas hydrophila (i.e., A. hydrophila), Aeromonas sobria (i.e., A. sobria), Edwardsiella tarda (i.e., E. tarda), Pseudomonas fluorescens (i.e., P. fluorescens), Acinetobacter baumannii (i.e., A. baumannii), drug-resistant S. aureus, drug-resistant A. baumannii, drug-resistant E. coli, Fusarium oxysporum (i.e., F. oxysporum), Fusarium graminearum (i.e., F. graminearum), or Fusarium solani (i.e., F. solani). A. sobria and E. tarda are obtained from Freshwater Fisheries Research Institute of Fujian. The drug-resistant S. aureus, the drug-resistant A. baumannii, and the drug-resistant E. coli are clinical isolates and are provided by the Second Affiliated Hospital of Fujian Medical University, and the rest of the bacterial strains are purchased from the China General Microbiological Culture Collection Center (CGMCC).

The specific method was as follows:

(1) Bacteria, such as S. aureus, S. epidermidis, E. faecium, E. faecalis, L. monocytogenes, E. coli, P. aeruginosa, A. hydrophila, A. sobria, E. tarda, P. fluorescens, A. baumannii, drug-resistant S. aureus, drug-resistant A. baumannii, and drug-resistant E. coli were inoculated on nutrient broth plates and cultured at appropriate temperatures for 18-24 hours. Fungi, such as F. oxysporum, F. graminearum, and F. solani were inoculated on potato dextrose and cultured at 28° C. for 1-7 days.

(2) The bacteria and the fungi were then inoculated on corresponding culture mediums: the bacteria and the fungi were further cultured for 18-24 hours. The bacteria were washed away from the corresponding culture medium with 10 mMol/L (mM) sodium phosphate buffer (pH=7.4) to obtain a suspension of the bacteria. The suspension of the bacteria was diluted with a mixture of Mueller Hinton (MH) medium and the sodium phosphate buffer to a final concentration of 3.3*10⁴ CFU/mL. Spores of the fungi were washed away from the corresponding culture medium with 10 mM of a sodium phosphate buffer (pH=7.4), and were then diluted with a mixture of the potato dextrose liquid and the sodium phosphate buffer. The concentration of the spores was determined under an optical microscope and adjusted to a final concentration of 5*10⁴ cells/mL.

(3) The Spampcin₅₆₋₈₆ was dissolved in sterilized MilliQ® water, filtered by a 0.22 μm pore size membrane, diluted to concentrations of 3 μM, 6 μM, 12 μM, 12 μM, 24 μM, 48 μM, and 96 μM, and placed on ice for use.

(4) A blank control group, a negative control group, and an experimental group of each of the bacteria and the fungi were set on 96-well cell culture plates, and each of the blank control group, the negative control group, and the experimental group has three parallel samples.

The blank control group a: 50 μL of the Spampcin₅₆₋₈₆ with 50 μL of the corresponding culture medium;

The negative control group b: 50 μL of sterilized MilliQ® water with 50 μL of the suspension of the bacteria or the suspension of the fungi; and

The experimental group c: 50 μL of the Spampcin₅₆₋₈₆ with 50 μL of the suspension of the bacteria or the suspension of the fungi.

(5) The 96-well cell culture plates were placed in an incubator at 28° C. and cultured for 1-2 days.

The results of MIC and MBC of the Spampcin₅₆₋₈₆ are shown in Table 2.

TABLE 2 Anti-bacterial activity and anti-fungal activity of the Spampcin₅₆₋₈₆ Microorganism CGMC NO. MIC MBC Gram-positive bacterium S. aureus 1.2465 1.5-3  3-6 L. monocytogenes 1.10753 1.5-3  1.5-3  E. faecalis 1.2135 1.5-3  1.5-3  E. faecium 1.131  0-1.5 1.5-3  S. epidermidis 1.4260 3-6 3-6 S. aureus QZ19133 —  6-12  6-12 S. aureus QZ19132 —  6-12 12-24 Gram-negative bacterium P. aeruginosa 1.2421 1.5-3  3-6 A. baumannii 1.6769 3-6 3-6 A. sobria — 3-6 3-6 A. hydrophila 1.2017  6-12  6-12 E. coli 1.2389 3-6 3-6 E. tarda — 3-6 24-48 P. fluorescens 1.3202 1.5-3  1.5-3  E. coli QZ20147 —  6-12  6-12 E. coli QZ20148 —  6-12  6-12 A. baumannii QZ20142 — 3-6 3-6 A. baumannii QZ20143 — 3-6  6-12 Fungi F. oxysporum 3.6785 3-6 3-6 F. graminearum 3.4521 1.5-3  1.5-3  F. solani 3.5840 1.5-3  3-6 Note: a-b represent minimum inhibitory concentration (MIC) (μM) and minimum bactericidal concentration (MBC) (μM). a: The highest concentration of the Spampcin₅₆₋₈₆ that induce visible growth of microorganisms. b: The lowest concentration of the Spampcin₅₆₋₈₆ that does not induce visible growth of microorganisms.

Embodiment 3: A bactericidal Kinetic Curve of the Spampcin₅₆₋₈₆

Staphylococcus Aureus (i.e., S. aureus), Pseudomona Aeruginosa (i.e., P. aeruginosa), Aeromonas hydrophila (i.e., A. hydrophila), and Escherichia coli (i.e., E. coli) were selected to test bactericidal kinetics of the Spampcin₅₆₋₈₆.

A specific method in Embodiment 3 is similar to the antimicrobial activity assay described in Embodiment 2. A final concentration of the Spampcin₅₆₋₈₆ was adjusted to 1×MBC (S. aureus: 6 μMol/L (μM); P. aeruginosa: 6 μM; A. hydrophila: 12 μM; and E. coli: 6 μM).

At 2, 8, 10, 20, 25, and 30 minutes of incubation, 6 μL of a suspension of S. aureus was diluted into 600 μL of Dulbecco's phosphate-buffered saline (DPBS) to obtain a first solution, 20 μL of the first solution was coated on a nutrient broth plate, and cultured at 37° C. for 1-2 days to record the number of S. aureus monoclonal, and the percentage of Colony-Forming Units (CFU) was calculated.

At 2, 4, 5, 10, 15, 20, and 30 minutes of incubation, 6 μL of the suspension of P. aeruginosa was diluted using 600 μL of the DPBS to obtain a second solution, 40 μL of the second solution was coated on the nutrient broth plate, and cultured at 37° C. for 1-2 days to record the number of P. aeruginosa monoclonal, and the percentage of CFU was calculated.

At 10, 30, 60, 120, and 150 minutes of incubation, 6 μL of the suspension of A. hydrophila was diluted using 720 μL of the DPBS to obtain a third solution, and 20 μL of the third solution was coated on the nutrient broth plate, and cultured at 28° C. for 1-2 days to record the number of A. Hydrophila monoclonal, and the percentage of CFU was calculated.

At 10, 15, 20, 30, and 60 minutes of incubation, 6 μL of the suspension of E. coli l was diluted using 720 μL of the DPBS to obtain a fourth solution, and 20 μL of the fourth solution was coated on the nutrient broth plate, and cultured at 37° C. for 1-2 days to record the number of E. coli monoclonal, and the percentage of CFU was calculated.

Referring to FIGS. 1A, 1B, 1C, and 1D, the percentage of CFU is defined relative to the CFU obtained in the control group.

Embodiment 4: The Thermal Stability of Anti-Bacterial Activity of the Spampcin₅₆₋₈₆

Staphylococcus aureus (i.e., S. aureus) and Pseudomona aeruginosa (i.e., P. aeruginosa) were selected to test the thermal stability of the anti-bacterial activity of the Spampcin₅₆₋₈₆.

A specific method in Embodiment 4 is similar to the antimicrobial activity assay described in Embodiment 2. A final concentration of the Spampcin₅₆₋₈₆ was adjusted to 1×MBC (S. aureus: 6 μMol/L (μM), P. aeruginosa: 6 μM) to obtain a Spampcin₅₆₋₈₆ solution. The Spampcin₅₆₋₈₆ solution was heated in boiling water for 10, 20, and 30 minutes, and then placed on ice for use. The Spampcin₅₆₋₈₆ was co-cultured with S. aureus or P. aeruginosa. OD₆₀₀ values were measured with a microplate reader at 0, 12, 24, 36, and 48 hours, and the results are shown in FIGS. 2A and 2B.

Embodiment 5: Microscopic Observations of Spore Germination of Fungi after Treatment with the Spampcin₅₆₋₈₆

Fusarium oxysporum (i.e., F. oxysporum) and Fusarium graminearum (i.e., F. graminearum) were selected to evaluate the effects of the Spampcin₅₆₋₈₆ on the spore germination of the fungi.

A specific method in Embodiment 5 is similar to the antimicrobial activity assay described in Embodiment 2. The concentration of the Spampcin₅₆₋₈₆ was adjusted to be 6 μMol/L (μM) and 12 μM. A final concentration of spores of F. oxysporum and F. graminearum was adjusted to be 5*10⁴ cells/mL. Each of the Spampcin₅₆₋₈₆ with the concentration of 6 μM and 12 μM and a corresponding one of the spores of F. oxysporum and F. graminearum were mixed to even in 96-well cell culture plates, and cultured for 24 hours at 28° C. The spore germination of F. oxysporum and F. graminearum was observed under an optical microscope, as shown in FIGS. 3A, 3B, 3C, 4A, 4B, and 4C.

Embodiment 6: Scanning Electron Microscope (SEM) Observation of Bacteria after Treatment with the Spampcin₅₆₋₈₆

Staphylococcus aureus (i.e., S. aureus) and Pseudomona aeruginosa (i.e., P. aeruginosa) were selected as testing strains, and a method for preparing SEM samples comprises the following steps:

(1) A suspension of S. aureus and P. aeruginosa (OD₆₀₀=0.4) are prepared according to the method described in Embodiment 2.

(2) The Spampcin₅₆₋₈₆ was dissolved with sterilized pure water and placed on ice for use, and the concentration of the Spampcin₅₆₋₈₆ was adjusted to be 12 μμMol/L (μM) Spampcin₅₆₋₈₆.

(3) The suspension of S. aureus was treated with the 12 μM Spampcin₅₆₋₈₆ with the same volume as the suspension of S. aureus at 37° C. for 10 minutes, and the suspension of P. aeruginosa was treated with the 12 μM Spampcin₅₆₋₈₆ with the same volume as the suspension of P. aeruginosa at 37° C. for 30 minutes.

(4) A fixative solution of glutaraldehyde with the same volume as the 12 μM Spampcin₅₆₋₈₆ was added, fixed at 4° C. for 2 hours to obtain first samples.

(5) The first samples were dehydrated in a series of concentration of 30%, 50%, 70%, 80%, 90%, 95%, 100%, and 100% (volume/volume (v/v)) of ethanol for 15 minutes to obtain second samples.

(6) After a gold spray, the second samples are observed and photographed by a scanning electron microscope (SEM). The results are shown in FIGS. 5A, 5B, 6A, and 6B.

Embodiment 7: Determination of Cytotoxicity of the Spampcin₅₆₋₈₆

Human embryonic kidney 293T cells (HEK-293T) and hemocytes of Scylla paramamosain (i.e., S. paramamosain) were selected to test the cytotoxicity effects of the Spampcin₅₆₋₈₆.

(1) The hemocytes of S. paramamosain and HEK-293T were harvested, and the cell concentrations of the hemocytes of the S. paramamosain and HEK-293T are adjusted to 1×10⁵ cells/mL to obtain cell suspensions. 100 μL of the cell suspensions were seeded in 96-well cell culture plates, and incubated at an appropriate temperature.

(2) The hemocytes of the S. paramamosain and HEK-293T were treated with the Spampcin₅₆₋₈₆ with different concentrations of (0, 3, 6, 12, 24, and 48 μM) for 24 hours.

(3) The hemocytes of the S. paramamosain and HEK-293T were treated with 20 μL of a 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium-phenazine methosulfate (MTS-PMS) reagent for another 2 hours, and then an absorbance value of each well of the 96-well cell culture plates was measured at 492 nm using a microplate reader to evaluate the cytotoxicity of the Spampcin₅₆₋₈₆, and the results are shown in FIGS. 7A and 7B.

The aforementioned embodiments are merely some embodiments of the present disclosure, and the scope of the disclosure is not limited thereto. Thus, it is intended that the present disclosure cover any modifications and variations provided they are made without departing from the appended claims and the specification of the present disclosure. 

What is claimed is:
 1. An antimicrobial peptide Spampcin₅₆₋₈₆ from Scylla paramamosain (Spampcin₅₆₋₈₆), wherein: a molecular formula of Spampcin₅₆₋₈₆ is C₁₅₄H₂₅₆N₅₄O₃₃S₃, and an amino acid sequence of Spampcin₅₆₋₈₆ is shown in SEQ ID NO:
 01. 2. A nucleic acid molecule encoding the Spampcin₅₆₋₈₆ according to claim
 1. 3. A method for preparing the Spampcin₅₆₋₈₆ according to claim 1, comprising: synthesizing the Spampcin₅₆₋₈₆ by a chemical solid-phase method.
 4. An application for using the Spampcin₅₆₋₈₆ according to claim 1, comprising: preparing an antimicrobial agent using the Spampcin₅₆₋₈₆, wherein: the antimicrobial agents have inhibitory or bactericidal effects on Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecium, Enterococcus faecalis, Listeria monocytogenes, Escherichia coli, Pseudomona aeruginosa, Aeromonas hydrophila, Aeromonas sobria, Edwardsiella tarda, Pseudomonas fluorescens, Acinetobacter baumannii, drug-resistant Staphylococcus aureus, drug-resistant Acinetobacter baumannii, and drug-resistant Escherichia coli.
 5. An application for using the Spampcin₅₆₋₈₆ according to claim 1, comprising: preparing an anti-fungal agent using the Spampcin₅₆₋₈₆, wherein: the anti-fungal agent has inhibitory or bactericidal effects on Fusarium oxysporum, Fusarium graminearum, or Fusarium solani.
 6. An application for using the Spampcin₅₆₋₈₆ according to claim 1, comprising: preparing a feed additive using the Spampcin₅₆₋₈₆ in preparation.
 7. An application for using the Spampcin₅₆₋₈₆ according to claim 1, comprising: inhibiting or killing Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecium, Enterococcus faecalis, Listeria monocytogenes, Escherichia coli, Pseudomona aeruginosa, Aeromonas hydrophila, Aeromonas sobria, Edwardsiella tarda, Pseudomonas fluorescens, Acinetobacter baumannii, drug-resistant Staphylococcus aureus, drug-resistant Acinetobacter baumannii, and drug-resistant Escherichia coli using the Spampcin₅₆₋₈₆.
 8. An application for using the Spampcin₅₆₋₈₆ according to claim 1, comprising: inhibiting or killing Fusarium oxysporum, Fusarium graminearum, or Fusarium solani using the Spampcin₅₆₋₈₆. 